Pharma BD Deal Intelligence
This is a reverse merger, not a full acquisition win/bust — Serapha's shell-merger into Boundless Bio delivered a $230M-financed pivot into gene editing, handing Serapha holders ~96.3% control while Boundless exits its ecDNA cancer program entirely and pays its own stockholders a ~$44-48M parting dividend.
Serapha reaches Nasdaq via Boundless shell with $230M for AATD base editor
Full analysis, sources & comparables →On June 23, 2026, Boundless Bio (Nasdaq: BOLD) and privately held Serapha Bio announced a definitive all-stock reverse merger, alongside a $230 million financing ($138M prior Series A plus $92M concurrent pre-closing investment). Serapha is developing an investigational in vivo base-editing therapy (a gene-editing prospect originating from China) for Alpha-1 Antitrypsin Deficiency (AATD). Pre-merger Serapha holders are expected to own ~96.3% and Boundless holders ~3.7% of the combined company, which will operate as Serapha Bio and trade under 'AATD'. Boundless plans a pre-closing cash dividend (~$44-48M) to its stockholders. Close expected Q4 2026. (Boundless exits its ecDNA cancer program in the combination.)
Serapha Bio is developing an in vivo base-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder causing lung and liver disease. The approach aims to correct the underlying SERPINA1 (PiZ) mutation directly in vivo. Serapha reaches Nasdaq via reverse merger with Boundless Bio and a $230M financing; the combined company (ticker AATD) is expected to advance the program through early clinical development. Financial deal terms are structured as an all-stock merger.
Boundless Bio and Serapha Bio announce an all-stock reverse merger plus $230M financing; Serapha holders to own ~96.3%, combined company renamed Serapha Bio (Nasdaq: AATD). Close expected Q4 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Serapha Bio, Inc. / Boundless Bio, Inc. (this deal) | 2026 | $230M | 58 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| AstraZeneca PLC / Amolyt Pharma | 2024 | $1.1B | 73 |
| Sanofi SA / Inhibrx Inc. | 2024 | $2.2B | 70 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2026 deals · Rare Disease deals